Overall verdict
Buy
6.6/10
1-year performance
-5.85%
Score breakdown
Down 5.9% over 1 year, 36% of the 52-week range.
Strongest: Profitability 9.2/10. Weakest: Growth 3.6/10.
25 analysts, target +0.3% vs the price.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.
It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia.
It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology ; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications ; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Sector
Health Care
Industry
Pharmaceuticals
Primary listing
Lse
United Kingdom
CEO
Pascal Claude Soriot
Founded
1992
Employees
96 100
Revenue / employee
624 822 USD
Next earnings
October 30, 2026
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
157.32 GBP
52-week low
98.92 GBP
1-year performance
-5.85%
Declining
Year-to-date performance
-12.56%
Declining
Drawdown
-23.74%
Marked drawdown
Position in the 52-week range
36% of range
Range: 128.51 GBP - 135.86 GBP (2 methods agree)
The price implies growth of 6.69% per year; the company grows at 21.21%.
Gross margin 73.9%, net margin 17.0%, ROIC 14.3%, ROE 22.1%.
Net margin
17.02%
Exceptional
Sector 10.02%|S&P 13.13%
Gross margin
73.92%
Exceptional
Return on equity (ROE)
22.06%
Exceptional
Sector 6.38%|S&P 16.52%
Return on invested capital (ROIC)
14.27%
Exceptional
Free cash flow margin (FCF)
17.84%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.05x
High
Margin stability
4.8 pts
Steady
Revenue to net income
Growth
3.6/10Revenue up 5.8% over 1 year, 15.7% a year over 5, EPS 21.2% a year over 5.
Revenue (trailing 12 months)
60.6Md USD
Revenue growth (1y)
5.84%
Solid
Revenue growth (3y)
23.79%
Solid
EPS growth (1y)
1.71%
Moderate
EPS CAGR (5y)
21.21%
Exceptional
EPS revisions (3 months)
-0.40%
Revised down
Valuation
6.1/10P/E 24.0x, forward P/E 20.6x, EV/EBITDA 13.8x, PEG 1.13. The multiple sits in the 2th percentile of its own 5-year history.
P/E (TTM)
24.0x
Fair
Sector 27.1x|S&P 23.5x
Forward P/E
20.6x
Expensive
EV / EBITDA
13.8x
Fair
Sector 15.4x|S&P 14.7x
PEG
1.13
Fair
Sector 0.93|S&P 0.87
Fair value (reverse DCF)
132.18 GBP
Undervalued
P/E vs its own 5-year history
among the 2% lowest valuations
Far cheaper than usual
Market cap
246Md USD
Financial strength
7.0/10Cash covers 15.4% of the debt, net debt/EBITDA 1.2x.
Net debt / EBITDA
1.2x
Solid
Gearing (net debt / equity)
54.14%
Solid
Cash
5.0Md USD
Cash / market cap
2.02%
Stretched
Cash / total debt
15.41%
Tight
Interest coverage
6.8x
Solid
Net debt
27.2Md USD
Equity
50.3Md USD
Closed daily candles, 2 years
Last close on October 9, 2026: 119.98 GBP
- MM20122.42
- MM50120.59
- MM200135.18
- RSI 1446.3
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-1.14%
200-day average slope, 3 months
-2.01%
50-day average slope, 1 month
-3.01%
Price structure
Lower lows
Bullish RSI divergence
Yes
20-day volatility
1.55 % per day
Volatility change
-13.23%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 7.72 (15) | 10.23 (25) | 63 172 (27) | 22 079 (19) | 11 900 (16) |
| 2027 | 9.01 (15) | 11.39 (25) | 67 050 (27) | 24 312 (19) | 13 838 (16) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of October 9, 2026.
Same sub-industry: 515 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BMY | 7.2 | 8.0 | 121Md USD | 13.0x | 18.9 % | 5.8 % | 14.3 % | 1.9x | 9.5 % | 31.9 % | ||
| 2 | LLY | 6.8 | 6.1 | 1.1T USD | 40.1x | 33.5 % | 47.7 % | 39.8 % | 1.2x | 1.6 % | 38.5 % | ||
| 3 | JNJ | 6.7 | 6.0 | 630Md USD | 30.3x | 21.5 % | 6.6 % | 17.5 % | 0.9x | 3.5 % | 37.6 % | ||
| 4 | AZN | 6.6 | 6.8 | 246Md USD | 24.0x | 17.0 % | 5.8 % | 14.3 % | 1.2x | 4.4 % | -5.9 % | ||
| 5 | ROP | 6.6 | 6.1 | 338Md USD | 23.3x | 20.3 % | 1.7 % | 21.8 % | 0.8x | 5.4 % | 23.2 % | ||
| 6 | NOVN | 6.4 | 6.4 | 259Md USD | 22.7x | 23.3 % | -2.0 % | 17.2 % | 1.0x | 6.3 % | 12.2 % | ||
| 7 | NOVO B | 6.2 | 7.4 | 166Md USD | 9.7x | 35.3 % | 2.1 % | 38.9 % | 0.7x | 6.9 % | -33.4 % | ||
| 8 | MRK | 5.7 | 4.3 | 359Md USD | 116.4x | 4.8 % | 4.9 % | 3.6 % | 1.2x | 4.5 % | 67.4 % | ||
| 9 | PFE | 4.8 | 4.4 | 161Md USD | 37.4x | 6.8 % | 2.6 % | 3.0 % | 2.3x | 6.8 % | 9.7 % |
